Vidaza, from Pharmion, was
approved for myelodysplastic syndromes, a bone marrow disorder marked by rapidly dividing immature blood cells that no longer respond to growth - control mechanisms.
The researchers treated 63 cancer cell lines (26 breast, 14 colorectal and 23 ovarian) with low - dose 5 - azacitidine (AZA), an FDA - approved
drug for myelodysplastic syndrome, that reverses epigenetic changes by stripping off the methyl group that silences the gene.
She points out that one well - known methylation inhibitor, azacytidine (Vidaza), is a standard
treatment for myelodysplastic syndrome, but the strategy of blanket - inhibition of methylation canâ $ ™ t be expected to work for all cancers.